- Home
- EFSC vs NVCR Comparison
EFSC vs NVCR Comparison
Compare EFSC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSC
- NVCR
- Stock Information
- Founded
- EFSC 1988
- NVCR 2000
- Country
- EFSC United States
- NVCR Jersey
- Employees
- EFSC N/A
- NVCR N/A
- Industry
- EFSC Major Banks
- NVCR Medical/Dental Instruments
- Sector
- EFSC Finance
- NVCR Health Care
- Exchange
- EFSC Nasdaq
- NVCR Nasdaq
- Market Cap
- EFSC 2.0B
- NVCR 1.8B
- IPO Year
- EFSC 1999
- NVCR 2015
- Fundamental
- Price
- EFSC $54.02
- NVCR $17.49
- Analyst Decision
- EFSC Strong Buy
- NVCR Buy
- Analyst Count
- EFSC 4
- NVCR 5
- Target Price
- EFSC $51.75
- NVCR $26.60
- AVG Volume (30 Days)
- EFSC 128.3K
- NVCR 1.3M
- Earning Date
- EFSC 10-21-2024
- NVCR 10-30-2024
- Dividend Yield
- EFSC 2.11%
- NVCR N/A
- EPS Growth
- EFSC N/A
- NVCR N/A
- EPS
- EFSC 4.72
- NVCR N/A
- Revenue
- EFSC $591,631,000.00
- NVCR $549,964,000.00
- Revenue This Year
- EFSC N/A
- NVCR $16.23
- Revenue Next Year
- EFSC $1.49
- NVCR $6.09
- P/E Ratio
- EFSC $11.27
- NVCR N/A
- Revenue Growth
- EFSC N/A
- NVCR 8.33
- 52 Week Low
- EFSC $34.26
- NVCR $10.87
- 52 Week High
- EFSC $54.88
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- EFSC 61.25
- NVCR 43.24
- Support Level
- EFSC $51.31
- NVCR $15.61
- Resistance Level
- EFSC $53.55
- NVCR $17.31
- Average True Range (ATR)
- EFSC 1.33
- NVCR 1.29
- MACD
- EFSC 0.18
- NVCR 0.05
- Stochastic Oscillator
- EFSC 100.00
- NVCR 11.59
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate, and consumer loans.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.